MRI Contrast Agents: Developments, Challenges, and Future Trends by Alshowiman, Sami S. et al.
Information and Knowledge Management                                                                                                                                        www.iiste.org 
ISSN 2224-5758 (Paper) ISSN 2224-896X (Online) 
Vol.8, No.5, 2018 
 
13 
MRI Contrast Agents: Developments, Challenges, and Future 
Trends 
 
Sami S. Alshowiman1*      Ayman K. Alswailem1      Omar A. Almohizy2  
Abdurrahman A. Alfawaz2*      Abdulaziz A .Ibn Alshaikh2 
This work was carried out in collaboration between all authors. Authors SSS and AKS 
Designed the study, wrote the protocol and wrote the first draft of the manuscript. Authors OAM. AAA and 
AAS managed managed the literature searches. All authors read and approved the final manuscript. 
1.Prince Sultan Cardiac center, Saudi Arabia 
2.Medical Services of Defense, Saudi Arabia 
 
Abstract  
Contrast agents in medicine are chemical materials used to improve tissue and fluid contrast in the body during 
medical imaging. It is mainly used in improving the visibility of blood vessels and the gastrointestinal tract. 
Some types of contrast materials are used in a medical imaging examination and can be classified according to 
the imaging technique used. The first contract agent dates back to 1988 which is called gadopentetate 
dimeglumine (Magnevist®) and was allocated for Magnetic Resonance Imaging (MRI). Then, I has become 
available in clinical use. Afterwards, many studies have examined the capability of MRI contrast agents to be 
used in diagnostic imaging in all parts of the body including the skin, the central nervous system, heart and 
circulation, breast, lungs, musculoskeletal and lymphatic systems, and even the gastrointestinal tract. Nowadays, 
MRI contrast agents are widely used in clinical practice and have expanded beyond the imitational expectations 
to be a key tool in disease diagnosis around the world. Contrast-Enhanced (CE) MRI keeps in development and 
new technologies have emerged and new agents were introduced, with great opportunity being provided to 
ensure better imaging and patient management practices. Also, new clinical challenges were associated with the 
progress in CE-MRI. This paper aims to overview the historical development of MRI and contrast materials in 
order to shed light on the clinical development of CE-MRI. Also, the paper overviews the contemporary 
perspectives and clinical challenges associated with CE-MRI with the provision of significant future trends.  
        
Introduction  
Magnetic Resonance Imaging (MRI) is one of the most advanced means of looking into the living human body. 
One of the advantages of this technique is that it does not use radiation that can cause damage (as in x-ray 
imaging). So, pregnanet women can use it safely. The year 2017 hearalded the 29th anniversary of the contrast 
empowerment in MRI technology. The first Gadolinium-Based Contrast Agent (GBCA), gadopentetate 
dimeglumine (Magnevist®), became available for clinical use globally in 1988 and, since then, eight further 
gadolinium chelates have been developed and approved in many regions worldwide.  
Progress in contrast materials and the technical capabilities of MRI have increased the accuracy and utility 
of contrast-enhanced-MRI (CE-MRI) for many different indications. Today, CE-MRI is a valuable and 
established diagnostic imaging tool worldwide, used annually in approximately 30 million procedures, with more 
than 300 million procedures performed to date (Data on file, Bayer HealthCare). The role of CE-MRI will 
continue to grow in the future as new imaging techniques are integrated into clinical practice. The close 
relationship between clinical diagnosis and the monitoring of increasingly specific therapies is one of the most 
important areas for CE- 
MRI use, along with research into new MRI contrast agents.  
This review attempts to outline the history of contrast material development in MRI, to describe current 
technologic trends and clinical challenges, and to provide an outlook on potential future developments. This 
paper is based on previously conducted studies and does not include any new studies of human or animal 
subjects performed by any of the authors.  
 
Research Questions  
This paper attempts to answer the following questions:  
1. What are the historical development stages that CE-MRI has undergone?  
2. What are the current trends of CE-MRI?  
3. What are the clinical challenges associated with CE-MRI development?  
4. What are the future perspectives of CE-MRI?  
 
MRI and Initial Contrast Materials Research  
Nuclear Magnetic Resonance (NMR) was discovered by Bloch, Bloembergen and Purcell in the 1940s (Bloch, 
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1946; Bloembergen et al., 1948). The first NMR images to be generated using the interaction of two magnetic 
gradients were not published, however, until 1973. This research was presented by Lauterbur (Lauterbur, 1973) 
and Mansfield (Garroway et al., 1974) who were awarded the Nobel Prize in Physiology or Medicine in 2003 for 
their work (Lauterbur, 2004). In 1974, Damadian was granted a patent for his NMR imaging technique, 
apparatus and method for detecting cancer in tissue (Damadian, 1974) and in 1977 he produced the first whole-
body MRI machine that generated images of a live human body (Damadian et al., 1977).  
The notion that proton relaxation times could be influenced by the presence of paramagnetic ions (with the 
promise of increased visibility of organs or body regions) was realized shortly after this in the late 1970s 
(Lauterbur et al., 1978). Research then began into suitable paramagnetic ion complexes for use as MRI contrast 
agents, beginning with animal studies of manganese (Mn2+) compounds (Brady et al., 1982; Goldman et al., 
1982; Mendonca et al., 1983) and ferric (Fe3+) chloride (Young et al., 1981).  
In 1982, Val Runge presented investigations of paramagnetic ions, including copper (Cu2+), chromium 
(Cr3+), Fe3+, Mn2+ and gadolinium (Gd3+) (Runge et al., 1983) outlining potential complexes that might be stable 
enough for clinical use as oral and intravenous contrast agents in  
MRI (Runge, 2008). A research group at Schering AG, Germany (now Bayer HealthCare), led by 
Weinmann, had recognized that Gd3+ was the most effective paramagnetic ion in terms of T1 relaxivity (and thus 
enhancement effect), and was developing gadopentetate dimeglumine, using the commercially available 
diethylenetriamine penta-acetic acid chelate (Gries et al., 1981). Clinical development collaboration between 
Weinmann and other centers, including Runge and Brasch, led to Runge receiving the American Society of 
Neuroradiology Dyke Award for demonstrating the utility of gadopentetate dimeglumine-enhanced MRI for 
brain imaging (Runge et al., 1985). Weinmann subsequently published a seminal paper on the characteristics of, 
and initial study results for, gadopentetate dimeglumine (Weinmann et al., 1984) which was, as of 2008, the 
most cited article ever published in the American Journal of Roentgenology (BuiMansfield, 2006).  
The first injection of gadopentetate dimeglumine in a human volunteer took place in Berlin on November 
10, 1983, as part of a Phase I trial, showing uniform enhancement of the bladder (Laniado et al., 1984). Reports 
of the human pharmacokinetics of gadopentetate dimeglumine (Weinmann et al., 1984) and the first patient 
series (Carr et al., 1984) followed shortly afterward, and further clinical trials were instigated in 1985. Based on 
the results of these clinical trials, gadopentetate dimeglumine was approved for clinical use in the United States, 
Germany and Japan in 1988: the world’s first contrast medium for MRI was launched.  
 
Action Mechanism and Pharmacology of GBCAs  
All Gadolinium-Based Contrast Agents (GBCAs) contain the paramagnetic ion of the rare earth metal 
gadolinium (Gd3+), which possesses the most unpaired electrons of any stable ion (seven), creating a high 
magnetic moment that is effective at enhancing proton relaxation (Caravan et al., 1999; Lin et al., 20070. 
Paramagnetic contrast media shorten the T1 (longitudinal) and T2  
(transversal) relaxation times of surrounding water protons to indirectly produce a signal enhancing effect 
(Lauffer, 1987). The efficiency of an agent to shorten relaxation times is called relaxivity, which is dependent on 
the ligand surrounding the Gd3+ ion and influenced by extrinsic factors including temperature, magnetic field 
strength and the tissue surroundings (water, plasma or blood). At approved clinical doses of GBCAs (typically 
between 0.1 and 0.3 mmol/kg body weight), the T1 relaxivity effect dominates and yields bright contrast (Cheng 
et al., 2012; Lauffer, 19990).  
Following intravenous injection, all GBCAs distribute in the blood and extravascular– extracellular space 
(Aime & Caravan, 2009; Staks et al., 1994). GBCAs are biologically inert and rapidly eliminated by the kidneys, 
with the exception of gadoxetic acid  
(Primovist®/Eovist®), gadobenate dimeglumine (Multihance®) and gadofosveset (Vasovist®/Ablavar®), 
which are in part taken up by hepatocytes and eliminated by the hepatobiliary system.  
As Gd3+ ions are toxic, they are chelated with organic ligands to create GBCAs with either a linear or 
macrocyclic structure. For GBCAs with a linear structure (e.g., Magenvist, MultiHance, or Ominscan), a 
polyamino-carboxylic acid backbone wraps around the Gd3+ ion, but does not fully enclose it, whereas in macro 
cyclic chalets (gadobutrol [Gadovist®], gadoterate meglumine  
[Ddexzotarem®], and gadoteridol [Prohance®]), a rigid “cage” with a preorganized cavity surrounds the ion. 
The structure of the GBCA determines its complex stability and stability in vivo. An in vitro study mimicking 
physiological serum conditions in renally impaired subjects demonstrated that linear agents, incubated over a 15-
day period, could release substantial amounts of their Gd3+, while none of the macro-cyclic agents (Gadavist, 
Dotarem, ProHance) showed detectable Gd3+ release (<0.1% during 15 days of incubation) (Frenzel et al., 2008). 
This study also demonstrated that for the macrocyclic agents, charge was not an influencing parameter on 
complex stability. However, in vivo, the majority of a GBCA dose is excreted within a few days, even in renally 
impaired patients; for example, the elimination half-life of gadobutrol is 90 min in healthy subjects (Staks et al., 
1994) and 7–26 h in those with kidney disease (Frenzel et al., 2008; Al Tantawi ,2018 ;Tombach et al., 2000).  
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Development and Characteristics of MR Contrast Agents  
After the introduction of gadopentetate dimeglumine, the use of CE-MRI as a diagnostic imaging tool has 
expanded rapidly. While it was understood that Gd3+ was the most effective paramagnetic ion for proton 
relaxation, other paramagnetic ions have been developed for use as MRI contrast agents, including Mn2+ 
(Bernardion et al., 1992) and iron oxide compounds (Stark et al., 1988). Today, contrast media are administered 
in about 25% of all MRI examinations, especially for the brain and spine, for MR angiography (MRA) and for 
MRI of the abdomen, breast and heart (Ferre et al., 2012).  
Five further extracellular GBCAs, exhibiting the same, passive distribution and renal excretion as 
gadopentetate dimeglumine, have been approved for clinical use (Restrepo et al., 2012; Serrano et al., 2012) 
gadoterate (1989), gadoteridol (1992), gadodiamide (Omniscan®; 1993), gadobutrol (1998) and gadoversetamide 
(Optimark™; 1999). With the approval of gadobenate (1998) and gadoxetic acid (2005), two agents entered the 
market which exhibited a different pharmacokinetic profile to the other GBCAs—in addition to extracellular 
distribution, these agents are taken up to different degrees by hepatocytes, and thus produce a unique 
enhancement of liver parenchyma with partial excretion in the bile. A third group of agents are those which, after 
intravenous injection, remain in the circulation for prolonged periods, allowing extended  
imaging times for MRA. These agents include gadofosveset and the ultra-small superparamagnetic iron 
oxide (USPIO) particles (which have limited commercial availability) (Bremerich et al., 2007)  
Gadolinium-based contrast agents differ in their ability to shorten relaxation times, as a function of their 
relaxivity and local tissue concentration (Rohrer et al., 2005) Gadobutrol was considered a ‘second-generation’ 
GBCA (Scott, 2013) owing to its higher concentration and relatively high relaxivity (and thus improved imaging 
capacity) compared with earlier agents. (Gadobutrol is the only GBCA formulated at a concentration of 1.0 M, 
twice that of other agents. Combined with its high relaxivity in plasma, gadobutrol provides the greatest T1 
shortening per volume of any currently available GBCA (Sieber, 2009).  
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Safety of MR Contrast Agents  
As a class of agents, contrast media are associated with a lower prevalence of hypersensitivity reactions than 
other drug classes, such as pain killers or antibiotics (Dona et al., 2012). Within contrast media, GBCAs are 
associated with fewer adverse drug reactions than non-ionic iodinated contrast media for X-ray and computed 
tomography (Forsting et al., 2010). The incidence of acute adverse reactions appears to be very low for all 
GBCAs (Bruder et al., 2011; Gennen et al., 2006). The favorable safety profiles of gadobutrol and gadopentetate 
dimeglumine have been extensively documented based on millions of applications (Gutierrez et al., 2012; Knopp 
et al., 2006; Matsumura et al., 2013; Prince & Palkowitsch, 2012).  
In early 2006, Grobner was the first to suggest a link between administration of a GBCA and development 
of nephrogenic systemic fibrosis (NSF), a rare but potentially fatal disorder in patients with end-stage renal 
disease (Voth et al., 2011; Grobner, 2006). Bayer HealthCare immediately initiated a major research program 
into this issue, including basic in vitro research and toxicologic and pharmacologic animal studies (Pietsch et al., 
2009) generating much of the evidence published on this topic. International expert bodies, including the Food 
and Drug  
Administration, the European Medicines Agency and the European Society of Urological Radiology, 
subsequently issued recommendations concerning the stability of GBCAs (Pietsch et al., 2009) classifying 
macrocyclic agents as having a lower risk for the development of NSF. The reported incidence of NSF is 
decreasing, possibly attributable to a greater awareness of at-risk patients, lower dosing of contrast agents and 
the more widespread use of macrocyclic agents (Pietsch et al., 2011).   
More recently, residual gadolinium has been detected in patients with normal renal function.  
Abnormal T1 shortening in the dentate nucleus and globus pallidus of the brain on unenhanced MRI was 
first described by Kanda et al., in patients who had previously undergone repeated CEMRI (Sieber et al., 20080. 
It has since been demonstrated that the strength of such T1 shortening correlates to the number of previous 
GBCA administrations (Sieber et al., 2008) and the dosedependent accumulation of gadolinium in the neuronal 
epithelium and interstitium (Sieber et al., 2009) Furthermore, akin to NSF, this phenomenon has been linked to 
previous administration of linear GBCA, but not macrocyclic agents (Sieber et al., 2008). The clinical 
consequences of gadolinium crossing the blood–brain barrier and being deposited in neuronal tissues is not yet 
clear, and further investigation into the biodistribution of gadolinium is warranted (Sieber et al.,  
2009).  
 
Main Advances in CE-MRI   
The domain of CE-MRI has experienced extensive developments (Steger-Hartmann et al., 2010).  
Examples of major advances are described in the following sections.  
 
Central Nervous System  
The first studies during GBCA development showed that CE-MRI had utility for brain imaging (Steger-
Hartmann et al., 2009) due to the possibility to enhance areas with a disrupted blood– brain barrier 
corresponding to tumors and many inflammatory/infectious disorders. GBCAs were also shown to enhance 
tumors with a clear delineation and differentiation from perifocal oedema. Imaging of primary and secondary 
central nervous system (CNS) tumors is now a major clinical application of routine CE-MRI with superior 
imaging performance and greater versatility compared with other imaging techniques including CT (Thomsen et 
al., 2013). CE-MRI provides information on the location, classification, and grade of lesions, assisting in 
directing biopsy, treatment planning and monitoring of the response to therapy. Higher relaxivity agents higher 
field strengths (e.g., 3 T or higher) and time-resolved imaging have improved image spatial and temporal 
resolution and quality, increasing sensitivity for detecting smaller metastatic lesions (Becker et al., 2012). Other 
current applications of CE-MRI in the CNS include the assessment of vascular disease (stroke and vascular 
malformations), and inflammatory, neurodegenerative and infectious diseases.  
Contrast-enhanced magnetic resonance imaging is the gold standard for imaging patients with multiple 
sclerosis (MS). Applications of MRI in MS were first investigated in the early 1980s, where the technique 
demonstrated superior ability to detect lesions in the brain and spinal cord compared with CT (Wang et al., 
2011). Enhancing MS lesions on CE-MRI signify new inflammatory activity and a breakdown of the blood–
brain barrier, whereas active and inactive lesions may be indistinguishable on unenhanced T2-weighted images. 
This enhancement pattern is valuable to monitor MS lesion activity and response to treatment (Kanda et al. 
2014). The value of CE-MRI for management of MS was reflected by inclusion of this modality in the 
McDonald criteria, originally in 2001 and later in the 2005 and 2010 revised guidelines [93, 94]. The principle of 
CNS perfusion imaging was first described in a rat model of cerebral blood volume and cerebral blood flow in 
1988. Ten years later, perfusion imaging was routinely used to demonstrate poorly perfused brain tissue in stroke 
patients that was not observable on T2weighted sequences (Errante et al., 2014). The kinetic parameters 
associated with perfusion imaging, such as relative cerebral blood flow (rCBF) and relative cerebral blood 
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volume (rCBV) estimates, have been defined, quantified, and validated against established techniques such as 
SPECT (single-photon emission CT). Perfusion sequences are now widely incorporated in MRI protocols to 
quantify the extent of ischemia and hypoperfused tissue, with capability to target and optimize reperfusion 
therapy.  
Functional MRI techniques such as perfusion imaging are being utilized for brain tumor imaging, based on 
the principle of increased tumor vascularity. Determination of a threshold value for rCBV on CE-MRI has shown 
predictive value for differentiating high- and low-grade cerebral tumors and such a threshold can predict lesion 
progression and the outcome for patients with such tumors (Quattrocchi et al., 2015). Other perfusion 
parameters, including mean transit time and time to peak enhancement, have also been investigated as predictive 
markers in brain tumor imaging, although they are subject to variability and their biological relevance remains 
unclear. Dynamic contrast-enhanced (DCE) MRI and dynamic susceptibility contrast (DSC) MRI have also 
found a role in tumor imaging to assess vascular permeability and angiogenesis, respectively. Furthermore, DCE 
and DSC are commonly applied in acute stroke imaging to assist the differential evaluation of reversibly and 
irreversibly injured tissue.  
Perfusion imaging techniques are advancing rapidly and a recently reported fast, time-resolved sequence 
with good spatial and temporal resolution has shown promise for the estimation of rCBF and rCBV for MS 
lesions; this technique is predicted to improve the quantification of haemodynamics in a range of cerebral 
pathologies (Kanda et al., 2015).  
 
Magnetic Resonance Angiography  
In the early 1990s, the imaging technique of contrast-enhanced MRA was described which ultimately allowed 
less invasive and more rapid assessment of the anatomy and blood flow of vascular structures than intra-arterial 
digital subtraction angiography (DSA), without the radiation burden of CT-based angiography techniques. 
Injecting contrast while the patient was inside the scanner and synchronizing the bolus peak arterial phase with 
acquisition of central kspace data demonstrated preferential arterial enhancement, without excessive venous or 
background tissue enhancement, providing favorable sensitivity and specificity for the diagnosis of stenoses and 
occlusions (McDonald et al., 2015). Although signal-to-noise ratio (SNR) on MR images usually decreases with 
accelerated imaging, development of a faster, breath-hold abdominal MRA technique in 1995 surprisingly 
provided improvements of 25–50% and 60– 120% in SNR and contrast-to-noise ratio, respectively, with 
significantly reduced motion-related image blurring compared to the slower free breathing technique. 
Introduction of a time-resolved sequence in 1996, using view sharing with oversampling of the center of k-space, 
provided additional temporal information on blood flow dynamics, while maintaining the excellent delineation of 
vessels provided by the breath-hold technique, and reducing the flow-related artifacts that were sometimes seen. 
It was further realized, in 1997, that correct GBCA bolus timing could approximately double SNR in the aorta 
and portal vein, and this subsequently led to the development of a number of semi-automated bolus detection 
tools for optimization of CEMRA acquisition. A further advance in MRA came in 1998 with the introduction of 
moving-bed techniques allowing the GBCA bolus to be tracked over four or five fields of view, providing ‘head-
to-toe’ angiographic images in a single examination (Port et al., 2008).  
Today, CE-MRA is widely used for imaging the vascular anatomy in patients with known or suspected 
peripheral arterial occlusive or aneurysmal disease, as well as various less commonly encountered conditions 
that affect the non-coronary vasculature. Through advances in technology and the availability of suitable contrast 
agents, CE-MRA has evolved into a real-time imaging technique that is a highly valuable alternative to CT 
angiography and intra-arterial DSA, with the advantages of avoiding ionizing radiation, iodinated contrast 
agents, and the need for arterial puncture or manipulation (as required for DSA), making MRA particularly 
useful in patients requiring repeated imaging. Radial/spiral acquisitions that oversample the center of kspace, 
combined with compressed sensing technology and iterative Bayesian reconstruction techniques, promise to 
accelerate these sparse MRA data acquisitions by several orders of magnitude (Rohrer et al., 2005).  
 
Cardiac Imaging  
Gadolinium-based contrast agent wash-in and wash-out characteristics were initially described to differentiate 
infarcted and normal myocardial tissue in a rabbit model in 1996, with marked differences in contrast kinetics 
between normal tissue, infarct rim and infarct core regions, which correlated with the severity of microvascular 
damage. Differentiation of areas of damaged myocardium from areas that are structurally intact using CE-MRI at 
10–20 min p.i. has been termed ‘delayed gadolinium enhancement’ or ‘late gadolinium enhancement’ (LGE) 
imaging. Various studies have found LGE imaging to be a fast, robust, and highly valuable method to determine 
myocardial viability in patients with left ventricular dysfunction.  The likelihood of improvement in regional 
myocardial contractility following revascularization is negatively correlated with the size of a myocardial 
infarction, as depicted by the transmural extent of hyperenhancement at pretreatment CE-MRI (Schmitt, 2007). 
LGE has also proved to be an accurate measure to detect myocardial scars, myocardial fibrosis, and myocarditis 
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(Port et al., 2008).  
Advances in MR hardware and software have also led to the widespread adoption of MR myocardial 
perfusion imaging (MPI) in patients with suspected coronary artery disease (CAD). In MR-MPI, the initial 
upslope of dynamic (time-resolved) perfusion CE-MRI signal enhancement under rest and stress (adenosine 
stimulation) accurately depicted significant CAD, compared with invasive coronary angiography as a Ref. 
Receiver operating characteristic analyses revealed a clear cut-off value enabling determination of significant 
CAD, with high sensitivity and specificity (88% and 90%, respectively) (Scott, 20130. A meta-analysis of trials 
investigating cardiac SPECT, positron emission tomography (PET) and MRI perfusion imaging confirmed the 
high diagnostic accuracy of MR-MPI for detection of obstructive CAD, with the benefit of avoiding the ionizing 
radiation associated with the other techniques. The superiority of combined LGE and perfusion cardiac imaging 
over SPECT for the diagnosis of coronary artery disease has also recently been established in a large, 
prospective multicenter trial. 3.0 T CEwhole-heart coronary angiography is undergoing preliminary clinical 
investigations and achieving encouraging results (Dona et al., 2012).  If this technique proves successful, it may 
form part of a ‘one-stop-shop’ examination of CAD, providing information on the anatomy of the heart and the 
large blood vessels (including the coronary artery), ventricular wall motion, cardiac function, the heart valves, 
myocardial perfusion, myocardial viability and cardiac metabolism.  
Today, cardiac MRI has the capability to visualize cardiac function and morphology, and has become a 
standard imaging modality in a range of clinical applications including assessment of valvular disease, 
myocarditis and cardiomyopathies, and congenital heart disease (Bruder et al., 2011).  
 
Abdomen  
The first CE-MRI examination of the liver was performed in 1984, as part of a case series investigating the 
efficacy and safety of gadopentetate dimeglumine-enhanced MRI. Assessment of the dynamic CE-MRI 
enhancement pattern has become key for the differentiation of benign and malignant lesions in the liver, 
pancreas and kidneys, as well as elsewhere in the body. Major advances in this field were the introduction of fast 
breath-hold techniques and effective respiratory triggering, which reduced respiratory- and motion-induced 
artifacts while improving the sensitivity of imaging (Geenen et al., 2006).  
Another major advance was the advent of hepato-specific contrast agents. The first liver-specific CE-MRI 
results were published in 1991, describing manganese dipyridoxal diphosphate enhancement of the liver 
parenchyma and clearance into the gallbladder (this agent has currently limited worldwide availability). 
Gadobenate dimeglumine was then demonstrated to exhibit a small amount of hepatic excretion in humans (3–
5%), meaning that a liver-specific imaging phase could be discerned during delayed imaging (1–2 h p.i.) (Knopp 
et al., 2006).  
The agent gadoxetic acid (primovist/eovist) was developed as a highly liver-specific contrast medium. 
Gadoxetic acid is excreted almost equally via the liver and kidneys in humans and provides an earlier hepato-
specific imaging time (15–20 min p.i.) compared with gadobenate  
(Prince et al., 2012). A seminal manuscript by Weinmann, published in 1991, described the preclinical 
results for gadoxetic acid, highlighting its protein binding properties, low toxicity and uptake properties in rat 
hepatocytes, predicting gadoxetic acid to play a future role as a hepatobiliary contrast agent for MRI in clinical 
practice. The clinical trials in humans that followed established the value of gadoxetic acid for liver MRI, and 
more specifically for the detection and differentiation of focal liver lesions in the cirrhotic and noncirrhotic liver. 
Reflecting the value of gadoxetic acid-enhanced MRI, this imaging method was included in the 2010 guidelines 
of the Japan Society of Hepatology for the diagnosis of hepatocellular carcinoma in chronic liver disease. More 
recently, further applications of gadoxetic acidenhanced MRI have been investigated, including for 
cholangiopancreatography and biliary imaging. The potential utility of gadoxetic acid-enhanced MRI has also 
been suggested for the assessment of the liver pre- and post-treatment (surgery or locoregional therapy), 
including the quantitative and regional assessment of liver function (Voth et al., 2006).  
Contrast-enhanced magnetic resonance imaging has also proven useful, alongside multidetector CT, for 
accurate and sensitive characterization of renal masses; however, MRI has shown particular value as a problem-
solving tool in this field, and advanced techniques, such as perfusion and diffusion imaging, are now being 
investigated for the assessment of renal lesions and renal function (MR nephrography).   
CE-MR enterography for imaging the small bowel provides similar spatial resolution and improved contrast 
resolution compared to CT for investigation of gastrointestinal tumors and inflammatory bowel disease, and it 
shows promise for the future in terms of differentiating active from chronic bowel disease and non-invasive 
monitoring of response to therapy. The advantage of eliminating ionizing radiation with CE-MRI compared with 
CT is particularly important in young patients with inflammatory bowel disease who require numerous repeated 
examinations over many years.  
Contrast-enhanced magnetic resonance imaging is becoming a standard modality to image malignancies in 
the pelvis, with analysis of dynamic contrast kinetics able to aid visualization of tumor vascularization and 
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differentiation of benign from malignant prostate and ovarian tumors. For such tumors, improved diagnostic 
confidence in assessment of lesion type, extension and response to therapy has been demonstrated for 
multiparametric MRI techniques combining DCE with other functional parameters, particularly diffusion-
weighted imaging (DWI) (Grobner, 2006).  
 
Breast  
Contrast-enhanced magnetic resonance imaging of breast lesions was reported in a preliminary study in 1986, 
and was shown to be more accurate than X-ray mammography and unenhanced MRI. In the following years, 
various technical developments were described (Carr et al., 1984). CE-MRI has since been demonstrated to 
detect more ductal carcinoma in situ than mammography, and in particular more high-grade disease, suggesting 
that CE-MRI is superior to mammography for diagnosis of the most clinically relevant, potentially invasive 
tumors. An explanation for the difference in performance between these modalities is that mammography 
demonstrates microcalcifications due to apoptosis of slowly growing cancers, whereas MRI detects changes in 
the local microvasculature indicative of aggressively growing cancers. CEMRI has also been shown to be highly 
sensitive for the detection of cancer foci in the contralateral breast of women diagnosed with unilateral disease. 
Furthermore, neither mammography nor ultrasound could improve the cancer yield provided by CE-MRI alone 
when screening women at risk (Lin & Brown, 2007).  
DCE enhancement kinetics have shown value for the evaluation of mass-like breast tumors, especially for 
morphologically equivocal lesions, with characteristic signal time–intensity curves able to differentiate benign 
from malignant tumors. Following early initial tumor enhancement, a signal intensity decline (type III ‘washout’ 
curve) or plateau (type II curve) is characteristic of invasive breast cancer, whereas benign masses tend to exhibit 
a type 1 curve with ‘persistent’ signal enhancement.   
Today, CE-MRI is an established tool for determining the morphological and functional characteristics of 
breast tumors, and is recommended by international societies for screening women with >20% lifetime risk of 
breast cancer, to aid exact local staging of the extent of disease, as a guide for biopsy, and to evaluate treatment 
response (Caravan  et al., 1999).  
 
Musculoskeletal System  
Magnetic resonance imaging has been used to image the musculoskeletal system since the early days of the 
modality, as MRI demonstrated good soft tissue contrast, spatial resolution and multiplanar capabilities, and 
sequences could be adapted for optimal contrast between muscle, bone marrow and abnormal tissue. The 
indications for musculoskeletal MRI fall into three main categories: tumors, infectious diseases and joint 
damage. CE-MRI is employed to gain additional information in cases of complicated osseous and soft-tissue 
infection (especially when extent and necrosis are of concern), and for the evaluation of articular injuries and 
post-operative joint status. For joint assessment, MR arthrography has become a useful alternative to 
conventional MRI, with GBCA administration performed intravenously (indirect arthrography) or into the target 
joint (direct arthrography). Higher magnetic field strength, specialized coils, and improvements in pulse 
sequences and post-processing have led to increased SNR and soft tissue contrast. Nonetheless, more recent 
technological advances have furthered the capabilities of musculoskeletal MRI, including kinematic imaging of 
joint motion, MR spectroscopy and cartilage mapping (Staks et al., 1994).  
 
Current Technological Trends and Clinical Challenges  
Contrast-enhanced magnetic resonance imaging has become accepted as a valuable non-invasive, efficient and 
safe diagnostic imaging modality that is utilized in radiology departments worldwide. Current trends in the use 
of existing MR technologies are toward a greater standardization—and simplification—of protocols across 
centers, with the benefits of uniform performance and interpretation of imaging studies. Continuing research is 
also extending the applications of current contrast agents, so that individual agents can now be used to image an 
increasing number of body regions in a single examination.  
MRI acquisition times have shortened substantially over the past 25 years by increasing gradient 
performance and with new acquisition methods utilizing k-space under sampling, parallel imaging and, more 
recently, compressed sensing. The wider availability of MRI scanners with a 3 T field strength has also brought 
possibilities for higher image quality and shorter scan times (Tombach et al., 2000).  
The growing importance of MRI as a diagnostic tool has been underpinned by its capacity for 
multiparametric data acquisition, including DWI, DCE, elastography and MR spectroscopy, alongside 
conventional MRI protocols. Multiparametric imaging has enabled more accurate assessment of normal and 
disease-associated tissue characteristics in terms of cellularity (diffusion restriction), vascularization (DSC), 
permeability (DCE), fibrosis and metabolite levels, leading to greater certainty of diagnosis and improved patient 
outcome. Multiparametric MRI is advancing imaging capabilities in many fields, with a special focus on 
indications where anatomical imaging alone has in the past been associated with limited accuracy, such as breast 
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and prostate cancer imaging (Bernardino, 1992). A recent trend in the development of MRI has been the 
investigation of integrated multimodality imaging, particularly MR/PET (Kanda er al., 2015). While PET/CT has 
been established as a diagnostic tool in cancer imaging for the past decade, MR/PET offers exciting possibilities 
for gathering extensive morphologic and hybrid (i.e. both PET and MRI) functional information. More research 
is required to establish the most appropriate clinical applications of MR/PET, based on diagnostic performance, 
technical feasibility, practicality and cost in relation to existing techniques. MR/PET techniques will also require 
changes in data acquisition, data processing, and image processing and interpretation when compared with 
PET/CT.  
The fast pace of technological innovation in MR is in itself a challenge for clinical practitioners. CE-MRI 
acquisition techniques are continually changing, and the modern radiologist must keep abreast of the latest 
developments while ensuring that others on the clinical team (nurses, technicians, etc.) are also appropriately 
educated and trained. As the reported applications of MRI continue to grow in the literature, there is a related 
need for expert recommendations to provide guidance on the optimal parameters and protocols, interpretation 
and reporting of the imaging results. For example, as described previously, dynamic CE-MRI perfusion 
parameters can aid in grading and predicting the progression of brain tumors and show promise as markers to 
monitor response to therapy; however, the variations in practice observed between centers indicate a need for a 
greater standardization of protocols and the utilization of the latest diagnostic algorithms (Errante et al., 2014).  
The role of CE-MRI in disease screening programs is an ongoing topic of discussion, with both health-
economic and clinical repercussions. CE-MRI has demonstrated high sensitivity and specificity for the detection 
of liver cancer and, as discussed above, CE-MRI of the breast provides a high cancer yield and is recommended 
for screening women at high risk. Currently, the imaging time and cost of a standard CE-MRI examination limits 
the use of MRI in screening programs. However, the feasibility of an MRI examination that uses limited 
sequences but retains sufficient sensitivity for screening is under discussion. This approach could shift the role of 
MRI in screening, decrease the cost per MRI examination and make MRI screening more cost-effective.  
 
Future Perspectives  
As the field of CE-MRI expands, there are many current research avenues and trends that in the future could 
prove important to clinical practice. In the following sections, four of these potentially interesting areas are 
discussed; however, we acknowledge that many more exciting avenues exist.  
 
Technological Advances: Higher Acceleration  
Newer signal processing technologies, such as compressed sensing and Bayesian iterative reconstruction 
methods are allowing the rapid acquisition of under sampled k-space data, permitting entire 3D images to be 
reconstructed from relatively few measurements. This technique allows acquisition of 3D data sets with 
preserved spatial resolution in a fraction of the standard examination time. Preliminary studies are demonstrating 
the capabilities of this technology, including clear visualization of the cerebral arteries and many branches on 
wholehead CE-MRA images (generated with an acceleration factor >100, 1 mm3resolution and a frame rate of 
approximately one full 3D dataset per second), functional cardiac MRI of the whole heart within one breath hold 
or using a free breathing technique, and high-resolution dynamic liver imaging at four frames per second 
(McDonald et al, 2015).  
This approach is likely to have an impact in many areas, initially for dynamic processes but eventually for 
all clinical MRI procedures, leading to an improved patient care through shorter and less invasive diagnostic 
examinations.  
 
Role of Contrast Agents  
Contrast media will be indispensable in most MRI examinations in the foreseeable future. The type of contrast 
medium selected and the dose that is injected will likely reflect changes in knowledge and techniques. Greater 
availability of MRI scanners with extended field of view coils and a 3 T field strength has provided an 
opportunity to improve the sensitivity of imaging and to allow contrast dose reduction without compromising 
image quality. Since a dose of contrast agent redistributes throughout the entire body, scanners with large coil 
arrays can be used to quickly screen extensive areas of anatomy, dramatically increasing the information 
obtained with a single injection (compared to imaging with scanners limited to a single station field of view). 
The number of CE-MRI procedures performed globally is likely to grow in the future, as the applications of MRI 
expand, as this modality becomes available to more patients, and as the information obtained from a single 
contrast injection increases. Technological advances are likely to facilitate the optimization of MRI protocols, 
reduce examination time while enriching the value of the MRI examination to the patient.  
 
Higher Relaxivity Contrast Agents  
Despite the major advances in CE-MRI in recent times, there are pathologies that cannot be fully assessed by 
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MRI. In order to increase the sensitivity of CE-MRI in certain pathologies, contrast agents with substantially 
higher relaxivity will be required.  
The efficiency of GBCAs, defined by their T1-relaxivity, is in part dependent on the number of water 
molecules directly bound to the Gd3+ complex (q), their mean residence time (τm) and the number and residence 
times of water molecules in the second hydration sphere (Quattrocchi et al., 2015). GBCAs induce proton 
relaxation by creating a fluctuating magnetic field, which can arise from tumbling of the molecule in solution 
(described by the rotational correlation time, τR) and excitation and relaxation of electrons in the Gd3+. Molecular 
size, rigidity of the Gd3+complex binding to a larger carrier molecule, and physiological protein binding all affect 
τR.  
At typical clinical magnetic field strengths (0.5–3 T), the greatest increases of T1-relaxivity for GBCAs 
have been achieved by slowing the tumbling (increasing τR) of complexes with q = 1 and water exchange rates 
(τm) of 10–30 ns (Wang et al., 2011). Relaxivity can be increased further by increasing q to 2; however, this 
reduces the stability of the complex. Water exchange dynamics and relaxivity can also be adapted by altering 
groups of atoms within the Gd3+ complex. Tumbling can be slowed (and relaxivity increased) by assembling 
larger molecules (nanometre scale) with numerous paramagnetic centers, but these molecules are limited in their 
distribution within the body due to their physical size (molecules >5 to 10 nm cannot freely leave the blood 
stream). Examples of this concept are experimental Gd complexes covalently bound to albumin, dextran or 
macromolecules (dendrimers), which have shown T1-relaxivities 3–5 times greater than clinically available 
agents. For magnetic field strengths of 3 T and above, the highest relaxivities can be achieved with intermediate 
τR (≤1 ns) and τm < 2 ns; however, such water residence times would be close to the shortest currently observed 
(1 ns) (Thomsen et al., 2013). The best strategy for raising relaxivity at high field strength is probably a 
moderate reversible binding to plasma proteins, a large second sphere of water molecules surrounding the 
Gdcomplex, and an increase in q; however, the benefits of the latter modification should be weighed against any 
reduction in complex stability. A number of studies using q = 2 and q = 3 have investigated this concept.   
 
Applications of Higher Relaxivity Contrast Agents  
Targeted Imaging  
Significant increases in relaxivity will allow substantial reductions in dose for novel agents and will facilitate the 
development of targeted/tissue-specific contrast media. Tissue-specific contrast agents are already available, 
such as gadoxetic acid, which is taken up by a hepatocyte uptake transporter (organic anion-transporting 
polypeptide 8) in liver parenchyma (Sieber et al., 2009) and the superparamagnetic iron oxide particles (SPIOs), 
which are sequestered by phagocytic Kupffer cells in the reticuloendothelial system of the liver. Other targeted 
agent approaches are at an experimental stage: investigations of ultra small SPIOs for imaging macrophage 
activity in lymph nodes and atherosclerotic plaque have been performed, as has labeling of tumors with 
monoclonal antibodies conjugated to paramagnetic complexes or superparamagnetic nanoparticles. However, the 
sensitivities of these techniques are not currently adequate for clinical applications, and new agents with 
significantly increased relaxivity targeted to specific tissues or disease processes will be required. One such 
experimental agent is EP-2104R, a molecule containing four Gd-complexes that binds with good specificity to 
fibrin, where it demonstrates a relaxivity per molecule approximately 25 times higher than a conventional GBCA 
at 1.4 T (Steger-Hartmann et al., 2009). The strong fibrin binding, selectivity and high relaxivity of EP-2104R 
enabled a clear depiction of occlusive intracranial thrombi in a rat embolic stroke model, where the Gd3+ 
concentration in the clot was 18-fold higher than in the blood pool. This agent has also demonstrated good 
visualization of thrombi in a swine model of pulmonary embolism, and could depict thrombi in the arterial and 
venous systems and hearts of patients (Steger-Hartmann et al., 2009).  
 
Monitoring Response to Therapy  
Early information on disease progression and response to therapy has considerable potential benefits for patient 
management, by promptly highlighting a need to shift therapeutic approaches and by providing cost savings if 
expensive therapies (e.g., anti-angiogenic agents) are quickly evaluated to be unsuccessful.  
A number of quantitative DCE and perfusion parameters are now considered biomarkers with value for the 
prediction and monitoring of therapeutic response, particularly to date in the oncologic and cardiologic 
specialties (Becker et al., 2012). For example, in oncology, perfusion mapping (as a surrogate measure of blood 
flow) correlates with response to tyrosine-kinase inhibitor therapy in patients with renal tumors, and quantitative 
kinetic parameters of lesion enhancement at DCE can predict whether triple-negative breast cancer patients will 
respond to neoadjuvant chemotherapy. Animal studies have suggested that quantitative tumor vascularity and 
perfusion parameters can act as surrogate descriptors for the effect of sorafenib therapy on prostate carcinoma 
within a week and that, in conjunction with novel contrast agents, the DCE MRI profile is able to indicate early 
(within 24 h) endothelial permeability changes following bevacizumab therapy in a melanoma model (Steger-
Hartmann et al., 2009).  
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Conclusion  
The domain of contrast materials in MRI has expanded beyond expectations since the approval of the first MRI 
contrast agent, gadopentetate dimeglumine, in the last three decades, and it continues to evolve. Today, CE-MRI 
is a valuable and established modality for multiple indications in many body regions. New techniques are 
bringing exciting novel possibilities for MRI, alongside associated clinical challenges.  
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